Cargando…

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

BACKGROUND: The optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase vs. alteplase for AIS within 4.5 hours of sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Huo, Wang, Xue, Quan, Xuemei, Chen, Shijian, Qin, Bin, Liang, Shuolin, Huang, Qiuhui, Zhang, Jian, Liang, Zhijian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274135/ https://www.ncbi.nlm.nih.gov/pubmed/37333014 http://dx.doi.org/10.3389/fneur.2023.1176540

Ejemplares similares

Tenecteplase and Alteplase for Thrombolysis of Acute Ischemic Stroke within 4.5 Hours: An Efficacy and Safety Study
por: Dhar, Nikita, et al.
Publicado: (2022)

Tenecteplase vs. alteplase for treatment of acute ischemic stroke: A systematic review and meta-analysis of randomized trials
por: Kobeissi, Hassan, et al.
Publicado: (2023)

Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit
por: Bivard, Andrew, et al.
Publicado: (2022)

Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review
por: Potla, Neha, et al.
Publicado: (2022)

Effectiveness of Standard-Dose vs. Low-Dose Alteplase for Acute Ischemic Stroke Within 3–4.5 h
por: Chen, Chih-Hao, et al.
Publicado: (2022)

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
por: Zhu, Annie, et al.
Publicado: (2022)

Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke
por: Nguyen, Chi Phuong, et al.
Publicado: (2023)

Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
por: Yang, Nan, et al.
Publicado: (2023)

A Comparative Study of Hemorrhagic Conversion Patterns After Stroke Thrombolysis With Alteplase Versus Tenecteplase
por: Ezzeldin, Mohamad, et al.
Publicado: (2023)

Replacing Alteplase with Tenecteplase: Is the Time Ripe?
por: Singh, Nishita, et al.
Publicado: (2023)

Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?
por: Vaishnav, Anand Girish
Publicado: (2022)

Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset
por: Wang, Zekun, et al.
Publicado: (2023)

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
por: Mahmood, Ammad, et al.
Publicado: (2022)

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
por: Logallo, Nicola, et al.
Publicado: (2014)

Recanalization before Thrombectomy in Tenecteplase vs. Alteplase-Treated Drip-and-Ship Patients
por: Seners, Pierre, et al.
Publicado: (2019)

Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
por: Shen, Ziyi, et al.
Publicado: (2023)

Economic evaluation of intravenous alteplase for stroke with the time of onset between 4.5 and 9 hours
por: Chen, Jigang, et al.
Publicado: (2023)

Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials
por: Xu, Na, et al.
Publicado: (2018)

Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
por: Mohan, Ayush, et al.
Publicado: (2023)

Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study
por: Wang, Lu, et al.
Publicado: (2023)

Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms
por: Urrutia, Victor C., et al.
Publicado: (2018)

The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt
por: Aref, Hany, et al.
Publicado: (2023)

Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns
por: Dong, Yi, et al.
Publicado: (2021)

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis
por: Xu, Jiawen, et al.
Publicado: (2023)

Tenecteplase Thrombolysis in Posterior Circulation Stroke
por: Alemseged, Fana, et al.
Publicado: (2021)

Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country–Nepal: Cost, Efficacy, and Safety
por: Nepal, Gaurav, et al.
Publicado: (2018)

Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion
por: Psychogios, Klearchos, et al.
Publicado: (2021)

Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial
por: Zhao, Zi-Ai, et al.
Publicado: (2023)

Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study
por: Teivane, Agnete, et al.
Publicado: (2022)

Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam
por: Mai, Duy Ton, et al.
Publicado: (2021)

Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs
por: Naidech, Andrew M., et al.
Publicado: (2020)

Risk Factors of Hypoperfusion on MRI of Ischemic Stroke Patients Within 7 Days of Onset
por: Xiao, Jingjing, et al.
Publicado: (2021)

Machine Learning-Based Model for Prediction of Hemorrhage Transformation in Acute Ischemic Stroke After Alteplase
por: Xu, Yanan, et al.
Publicado: (2022)

The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials
por: Abuelazm, Mohamed, et al.
Publicado: (2022)

Impact of Intravenous Alteplase Door-to-Needle Times on 2-Year Mortality in Patients With Acute Ischemic Stroke
por: Bhatt, Nirav R., et al.
Publicado: (2021)

Association of White Blood Cell Count With Clinical Outcome Independent of Treatment With Alteplase in Acute Ischemic Stroke
por: Barow, Ewgenia, et al.
Publicado: (2022)

Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset
por: Kate, Mahesh, et al.
Publicado: (2018)

Penumbral Imaging-Based Thrombolysis with Tenecteplase Is Feasible up to 24 Hours after Symptom Onset
por: Kate, Mahesh, et al.
Publicado: (2018)

Tenecteplase in Ischemic Stroke: Challenge and Opportunity
por: Li, Guangshuo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u434o3nf788jt3h32l06ichr9r